<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04398329</url>
  </required_header>
  <id_info>
    <org_study_id>HTX-034-101</org_study_id>
    <nct_id>NCT04398329</nct_id>
  </id_info>
  <brief_title>Dose-Escalation Study of HTX-034 Following Bunionectomy</brief_title>
  <official_title>A Phase 1b/2, Randomized, Blinded, Active-Controlled Study of Escalating Doses of HTX-034 for Postoperative Analgesia in Subjects Undergoing Unilateral, First Metatarsal Bunionectomy With Osteotomy and Internal Fixation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heron Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heron Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b/2, randomized, blinded, active-controlled study. Phase 1b will evaluate&#xD;
      escalating doses of HTX-034 compared with bupivacaine HCl. Phase 2 will be a dose-expansion&#xD;
      phase to evaluate additional subjects treated with the HTX-034 dose selected based on Phase&#xD;
      1b compared with bupivacaine HCl.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2020</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-emergent adverse events (TEAE's) (Phase 1B)</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean area under the curve (AUC) of the NRS scores through 72 hours (AUC0-72) for the pooled Phase 1b and Phase 2</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) of HTX-034</measure>
    <time_frame>29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum plasma concentration (Tmax) of HTX-034</measure>
    <time_frame>29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from Time 0 to the time of the last quantitative concentration (AUClast) of HTX-034</measure>
    <time_frame>29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from Time 0 extrapolated to infinity (AUCinf) of HTX-034 (Phase 1B)</measure>
    <time_frame>22 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal half-life (t½) of HTX-034 (Phase 1B)</measure>
    <time_frame>22 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean AUC of the NRS pain intensity scores</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total postoperative opioid consumption (in IV Morphine Milligram Equivalents)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who are opioid-free</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse Events (SAE's)</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Bunions</condition>
  <arm_group>
    <arm_group_label>Phase 1b (Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose level of HTX-034.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individualized doses of HTX-034.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 (Dose C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose of HTX-034 selected from Phase 1b.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 (Dose D)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose of HTX-034 selected from Phase 1b.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b and Phase 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivacaine HCl.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTX-034</intervention_name>
    <description>HTX-034, Dose A</description>
    <arm_group_label>Phase 1b (Cohort 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTX-034</intervention_name>
    <description>HTX-034, Dose B</description>
    <arm_group_label>Phase 1b (Cohort 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Luer lock applicator</intervention_name>
    <description>Applicator for instillation</description>
    <arm_group_label>Phase 1b (Cohort 1)</arm_group_label>
    <arm_group_label>Phase 1b (Cohort 2)</arm_group_label>
    <arm_group_label>Phase 2 (Dose C)</arm_group_label>
    <arm_group_label>Phase 2 (Dose D)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTX-034</intervention_name>
    <description>HTX-034, Dose C</description>
    <arm_group_label>Phase 2 (Dose C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTX-034</intervention_name>
    <description>HTX-034, Dose D</description>
    <arm_group_label>Phase 2 (Dose D)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine HCl</intervention_name>
    <description>Bupivacaine HCl, 50 mg</description>
    <arm_group_label>Phase 1b and Phase 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is medically fit to undergo an elective unilateral, first metatarsal bunionectomy with&#xD;
             osteotomy and internal fixation under regional anesthesia; no neuraxial technique (eg,&#xD;
             no spinal, epidural, or general anesthesia).&#xD;
&#xD;
          -  Has an American Society of Anesthesiologists (ASA) Physical Status of I, II, or III.&#xD;
&#xD;
          -  Female subjects are eligible only if not pregnant, not lactating, not planning to&#xD;
             become pregnant during the study; sterile, or using acceptable contraceptives.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Had contralateral foot bunionectomy in the past 3 months.&#xD;
&#xD;
          -  Has a planned concurrent surgical procedure.&#xD;
&#xD;
          -  Has a contraindication or a known or suspected history of hypersensitivity or&#xD;
             clinically significant idiosyncratic reaction to required study medications.&#xD;
&#xD;
          -  Has a pre-existing concurrent acute or chronic painful physical/restrictive condition&#xD;
             expected to require analgesic treatment in the postoperative period for pain.&#xD;
&#xD;
          -  Has received or is taking a contraindicated or prohibited medications.&#xD;
&#xD;
          -  Received an investigational product or device in a clinical trial within 30 days or&#xD;
             within 5 elimination half lives.&#xD;
&#xD;
          -  Has a known or suspected history of drug abuse, a positive drug screen on the day of&#xD;
             surgery, or a recent history of alcohol abuse.&#xD;
&#xD;
          -  Has a history of clinically significant cardiac abnormality such as myocardial&#xD;
             infarction within 6 months.&#xD;
&#xD;
          -  Has a history of coronary artery bypass graft surgery within 12 months.&#xD;
&#xD;
          -  Has a history of known or suspected coagulopathy.&#xD;
&#xD;
          -  As per subject history and/or medical records, has active infection or is currently&#xD;
             undergoing treatment for Hepatitis B, Hepatitis C, or human immunodeficiency virus&#xD;
             (HIV).&#xD;
&#xD;
          -  Has uncontrolled anxiety, psychiatric, or neurological disorder.&#xD;
&#xD;
          -  Had a malignancy in the last year, with the exception of nonmetastatic basal cell or&#xD;
             squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.&#xD;
&#xD;
          -  Has undergone 3 or more surgeries within 12 months.&#xD;
&#xD;
          -  Has a known history of glucose-6-phosphate dehydrogenase deficiency.&#xD;
&#xD;
          -  Has any of the following laboratory abnormalities during Screening (1 retest&#xD;
             permitted):&#xD;
&#xD;
               -  Severe liver function impairment.&#xD;
&#xD;
               -  Severe kidney function impairment.&#xD;
&#xD;
               -  Platelet count &lt;100,000/μL, hemoglobin &lt;12 g/dL, or hematocrit &lt;35%.&#xD;
&#xD;
          -  Has a body mass index (BMI) &gt;39 kg/m2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Juan Maya, MD</last_name>
    <phone>(858) 251-7269</phone>
    <email>jmaya@herontx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endeavor Clinical Trials, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>JBR Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 18, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Analgesia</keyword>
  <keyword>Bunionectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bunion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

